Glycosylation engineering of antibodies for improving antibody-dependent cellular cytotoxicity

Number of patents in Portfolio can not be more than 2000

United States of America Patent

PATENT NO 9718885
APP PUB NO 20160208009A1
SERIAL NO

14796909

Stats

ATTORNEY / AGENT: (SPONSORED)

Importance

Loading Importance Indicators... loading....

Abstract

See full text

The present invention relates to the field glycosylation engineering of proteins. More particular, the present invention is directed to the glycosylation engineering of proteins to provide proteins with improved therapeutic properties, e.g., antibodies, antibody fragments, or a fusion protein that includes a region equivalent to the Fc region of an immunoglobulin, with enhanced Fc-mediated cellular cytotoxicity.

Loading the Abstract Image... loading....

First Claim

See full text

Family

Loading Family data... loading....

Patent Owner(s)

Patent OwnerAddress
ROCHE GLYCART AGWAGISTRASSE 18 SCHLIEREN 8952

International Classification(s)

Inventor(s)

Inventor Name Address # of filed Patents Total Citations
Bailey, James E Agoura Hills, US 30 1601
Jean-Mairet, Joël Barcelona, ES 16 219
Umaña, Pablo Zürich, CH 95 705

Cited Art Landscape

Load Citation

Patent Citation Ranking

Forward Cite Landscape

Load Citation

Maintenance Fees

Fee Large entity fee small entity fee micro entity fee due date
7.5 Year Payment $3600.00 $1800.00 $900.00 Feb 1, 2025
11.5 Year Payment $7400.00 $3700.00 $1850.00 Feb 1, 2029
Fee Large entity fee small entity fee micro entity fee
Surcharge - 7.5 year - Late payment within 6 months $160.00 $80.00 $40.00
Surcharge - 11.5 year - Late payment within 6 months $160.00 $80.00 $40.00
Surcharge after expiration - Late payment is unavoidable $700.00 $350.00 $175.00
Surcharge after expiration - Late payment is unintentional $1,640.00 $820.00 $410.00